S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:SAVA

Cassava Sciences - SAVA Stock Forecast, Price & News

$20.42
+0.57 (+2.87%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$19.74
$21.32
50-Day Range
$16.33
$30.85
52-Week Range
$13.84
$124.80
Volume
1.35 million shs
Average Volume
2.24 million shs
Market Capitalization
$818.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$129.50

Cassava Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
534.2% Upside
$129.50 Price Target
Short Interest
Bearish
28.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.46mentions of Cassava Sciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.93) to ($1.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

597th out of 1,135 stocks

Pharmaceutical Preparations Industry

304th out of 557 stocks

SAVA stock logo

About Cassava Sciences (NASDAQ:SAVA) Stock

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Wall Street Analyst Weigh In

Several research firms have commented on SAVA. HC Wainwright reissued a "buy" rating on shares of Cassava Sciences in a research note on Thursday, August 4th. B. Riley lowered their target price on shares of Cassava Sciences from $58.00 to $44.00 and set a "buy" rating on the stock in a research note on Thursday.

Cassava Sciences Stock Performance

Shares of NASDAQ:SAVA traded up $0.57 during trading hours on Friday, hitting $20.42. 1,350,242 shares of the company's stock traded hands, compared to its average volume of 2,239,504. Cassava Sciences has a 52 week low of $13.84 and a 52 week high of $124.80. The company's fifty day simple moving average is $24.05 and its two-hundred day simple moving average is $29.90.

Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

SAVA Stock News Headlines

Cassava Sciences Responds to Media Reports
SAVA August 5th Options Begin Trading
The 7 Best Meme Stocks to Buy Now
See More Headlines
Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

SAVA Company Calendar

Last Earnings
11/10/2021
Today
8/14/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAVA
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$129.50
High Stock Price Forecast
$215.00
Low Stock Price Forecast
$44.00
Forecasted Upside/Downside
+534.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-32,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.45 per share

Miscellaneous

Free Float
36,048,000
Market Cap
$818.84 million
Optionable
Not Optionable
Beta
0.68

Key Executives

  • Mr. Remi Barbier (Age 62)
    Founder, Chairman, Pres & CEO
    Comp: $1.74M
  • Mr. Eric J. Schoen (Age 54)
    Chief Financial Officer
    Comp: $776.93k
  • Dr. Nadav Friedmann M.D. (Age 79)
    Ph.D., Chief Medical Officer & Director
    Comp: $765k
  • Dr. James W. Kupiec M.D.
    Chief Clinical Devel. Officer
  • Dr. George Thornton
    Sr. VP of Technology
  • Mr. Michael Zamloot
    Sr. VP of Technical Operations
  • Dr. Lindsay H. Burns Ph.D.
    Sr. VP of Neuroscience













SAVA Stock - Frequently Asked Questions

Should I buy or sell Cassava Sciences stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SAVA shares.
View SAVA analyst ratings
or view top-rated stocks.

What is Cassava Sciences' stock price forecast for 2022?

4 Wall Street analysts have issued 12-month target prices for Cassava Sciences' shares. Their SAVA share price forecasts range from $44.00 to $215.00. On average, they predict the company's share price to reach $129.50 in the next year. This suggests a possible upside of 534.2% from the stock's current price.
View analysts price targets for SAVA
or view top-rated stocks among Wall Street analysts.

How have SAVA shares performed in 2022?

Cassava Sciences' stock was trading at $43.70 on January 1st, 2022. Since then, SAVA shares have decreased by 53.3% and is now trading at $20.42.
View the best growth stocks for 2022 here
.

When is Cassava Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our SAVA earnings forecast
.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) released its earnings results on Wednesday, November, 10th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.09.

When did Cassava Sciences' stock split?

Cassava Sciences shares reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

What is Cassava Sciences' stock symbol?

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Group One Trading L.P. (0.00%), Northern Trust Corp (0.89%), Sculptor Capital LP (0.00%), JPMorgan Chase & Co. (0.14%), SG Americas Securities LLC (0.00%) and Rhumbline Advisers (0.12%). Insiders that own company stock include Eric Schoen, Remi Barbier and Sanford Robertson.
View institutional ownership trends
.

How do I buy shares of Cassava Sciences?

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cassava Sciences' stock price today?

One share of SAVA stock can currently be purchased for approximately $20.42.

How much money does Cassava Sciences make?

Cassava Sciences (NASDAQ:SAVA) has a market capitalization of $818.84 million. The company earns $-32,380,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

How can I contact Cassava Sciences?

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The official website for the company is www.cassavasciences.com. The company can be reached via phone at (512) 501-2444, via email at ir@paintrials.com, or via fax at 512-501-0414.

This page (NASDAQ:SAVA) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.